Welcome to our dedicated page for Kezar Life Sciences SEC filings (Ticker: KZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kezar Life Sciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kezar Life Sciences's regulatory disclosures and financial reporting.
Kezar Life Sciences reported it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The current report furnishes that press release as Exhibit 99.1 and incorporates it by reference. The filing also includes a Cover Page Interactive Data File as Exhibit 104.
The company states that the information furnished under Item 2.02, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly stated. No additional financial detail or analysis is included within this report.
Form 4 Filing Details: Micki Klearman, Director at Kezar Life Sciences (KZR), received a stock option grant on June 18, 2025. The transaction involves the acquisition of 5,000 stock options with the following key terms:
- Exercise price set at $4.46 per share
- Options expire on June 17, 2035
- 100% vesting scheduled for June 18, 2026, contingent on continued service
- Underlying security is Common Stock
This Form 4 filing, signed by Marc Belsky as Attorney-in-Fact on June 23, 2025, represents a standard director compensation equity grant. The options provide Klearman with the right to purchase 5,000 shares of Kezar Life Sciences common stock upon vesting, aligning the director's interests with those of shareholders through long-term equity ownership potential.
Kezar Life Sciences Director Michael Kauffman received a stock option grant on June 18, 2025, according to a Form 4 filing. The derivative security details include:
- Grant of 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
The transaction represents a standard director compensation grant. Kauffman holds the options directly, with no indirect beneficial ownership reported. The filing was signed by Marc Belsky as attorney-in-fact on June 23, 2025.
Director Courtney Wallace of Kezar Life Sciences received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- 100% vesting scheduled for June 18, 2026, contingent on continued service
- Options expire on June 17, 2035
This grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity incentives. The Form 4 was filed within the required reporting timeline, signed by Marc Belsky as attorney-in-fact on June 23, 2025.
Elizabeth Garner, Director at Kezar Life Sciences (KZR), received a stock option grant on June 18, 2025. The derivative securities transaction details include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
This Form 4 filing represents a standard director compensation equity grant. The options provide Garner with the right to purchase company shares at a fixed price, aligning her interests with shareholders over the long term. The one-year cliff vesting schedule incentivizes retention and continued service on the board.
Director Graham K. Cooper of Kezar Life Sciences received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The transaction details include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
This grant represents standard director compensation and was filed within the required reporting timeframe. The options provide Cooper with the right to purchase Kezar shares at a fixed price over the next decade, aligning his interests with shareholders' long-term value creation.
The Form 4 filing dated 06/23/2025 discloses that Kezar Life Sciences (KZR) director Franklin M. Berger received a new equity incentive on 06/18/2025.
- Instrument: Non-qualified stock option covering 5,000 common shares.
- Exercise price: $4.46 per share.
- Vesting: 100 % cliff vest on 06/18/2026, contingent upon continued service.
- Expiration: 06/17/2035 (10-year term).
- Post-grant holdings: 5,000 derivative securities, held directly.
No non-derivative share transactions were reported and no shares were sold. The filing represents a routine incentive grant, typical for board members, and does not signal a change in ownership control or near-term liquidity activity.